Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652678 · ClinicalTrials.gov registry record
Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Terminated
- Registry status
- 38
- Enrollment target
NCT00652678: Clinical Trial study, sponsored by State University of New York - Upstate Medical University.
NCT00652678 is a clinical trial that was terminated before completion, run by State University of New York - Upstate Medical University. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652678 was terminated before completion, sponsored by State University of New York - Upstate Medical University.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Some patients who undergo breast cancer treatment with lumpectomy followed by radiation therapy develop significant late skin and soft tissue changes, resulting in a poor cosmetic outcome. The goal of this study is to try to predict severe tissue reactions by using a combination of three of the latest blood tests, one of which we have developed ourselves.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-08 |
Why NCT00652678 stopped before completion
NCT00652678 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00652678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00652678 about?
NCT00652678 is a clinical study titled "Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients". Some patients who undergo breast cancer treatment with lumpectomy followed by radiation therapy develop significant late skin and soft tissue changes, resulting in a poor cosmetic outcome. The goal of this study is to try to predict severe tissue reactions by using a combination of three of the late...
What is the current status of trial NCT00652678?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2006-08. Estimated completion is 2012-08.
Who is sponsoring clinical trial NCT00652678?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia